Answers are grounded in this paper and cite their sources.
Introduction Obstructive sleep apnea (OSA) affects up to 1 billion people worldwide. Despite availability of continuous positive airway pressure (CPAP) therapy as the main treatment modality, a need for additional pharmacologic agents remains. Pharmacologic therapies can help improve patient symptoms of sleepiness and address the underlying mechanisms (endotypes) of disordered breathing in patients with OSA.Areas covered Potential pharmacologic target therapy of the four main OSA endotypes, airway collapsibility, poor upper airway muscle dilation, high loop gain, and low arousal threshold, are reviewed. Medications to help with daytime sleepiness are also discussed. Both original research and review articles spanning 2000 to 2026 are included in this review. Published articles were identified through PubMed and in-progress studies were identified through field experts.Expert opinion The current landscape of pharmacologic options for OSA is very exciting, especially with the expansion in number of agents addressing obesity that also help improve airway collapsibility. However, many of these therapies (apart from anti-obesity medications and medications for daytime sleepiness) are still experimental. Further evaluation is required before many of these pharmacologic agents are officially approved for use with or without CPAP. Agents addressing specific endotypes will pave the way for more personalized OSA treatment.
No takes yet. Share an insight, caveat, or question.
Bird et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: